Hot Features
Premium
Level up your trading with our powerful tools and real-time insights all in one place.
Lululemon Athletica Inc. (NASDAQ:LULU): The stock is currently trading at $70.09, up 2.19 percent from its previous close of $68.59. Lululemon Athletica reported its third quarter results but provided conservative outlook for the fourth quarter.
The company reported its earnings for the third quarter at 39 cents per share, beating consensus estimate of 37 cents per share. It had earned 27 cents per share during the corresponding quarter of the last year. Lululemon Athletica also surpassed street estimates of $305.6 million in revenue by reporting its revenue at $316.5 million. The stock is trading at the Price Earnings ratio of 46.19. It has traded in the range of $42.75 and $81.09 in the past 52 weeks. Lululemon Athletica expects to earn between 71 cents and 73 cents per share for its fourth quarter. The company is likely to report its fourth quarter revenue in the range of $475 million and $480 million. Lululemon Athletica stock is trading above its 20 days moving average price of $69.26 and 50 days moving average price of $69.44.
H&R Block Inc. (NYSE:HRB): The stock is trading higher despite posting loss for its second quarter. The company stock is currently trading at $17.93, up 3.22 percent from its previous close of $17.37. The stock had opened at $17.59 and has traded in the range of $17.59 and $18.40 in the current trading session. H&R Block Inc. posted lower than expected loss at $101 million, down from $123 million it had suffered in the corresponding quarter of the last year. The company’s revenue for the quarter stood at $137 million. It had reported its previous year quarterly revenue at $129 million. H&R Block Inc. stock commands the Price Earnings ratio of 15.70. Its stock is trading above its 20 days moving average price of $69.26 and 50 days moving average price of $69.44. H&R Block reported higher revenue from Australia, however it also bore the brunt of shrinking mortgage business. The company typically posts lower Q2 numbers due to its reliance on tax filing business.
Smithfield Foods Inc. (NYSE:SFD): The company beat consensus estimates for its fiscal second quarter numbers. The stock is currently trading at $23.21, up 1.35 percent from its previous close of $22.90. Smithfield Foods also received ratings upgrade from BB&T. The stock’s new rating is Buy, up from Hold. The stock is trading at the Price Earnings ratio of 10.95. It has traded in the range of $23.06 and $23.66 in the current trading session. Smithfield Foods’ quarterly net income fell to $10.9 million. Its previous year quarterly income was at $120.7 million. ON per share basis, its adjusted net income stood at 61 cents per share, beating consensus estimate of 44 cents per share. The company’s revenue lagged behind consensus expectation of $3.26 billion, by posting $3.23 billion, down 2.6 percent. However, the stock is trading below its 20 days moving average price of $23.31 and 50 days moving average price of $23.38. Analysts expect the company to report its third quarter earnings at 52 cents.
Hi Tech Pharmacal Co. Inc. (NASDAQ:HITK): The stock surged on the news of its strong quarterly numbers. The company reported 1 percent increase in its quarterly revenue to $57.5 million, beating consensus estimate of $55 million in revenue. Hi Tech is currently trading at $35.45, up 14.17 percent from its previous close of $31.05. The stock is trading at the Price Earnings ratio of 11.93. Hi Tech Pharmacal earned 66 cents per share in income. It was expected to report its earnings at 52 cents per share. The company reported that its revenue was partly hurt due to Sandy storm as the company could not ship the products. The stock has traded in the range of $32.65 and $35.87 in the current session, while its 52 weeks price movement has been in the range of $27.35 and $43.08. The stock is trading above its 20 days moving average price of $31.32 and 50 days moving average price of $31.33. Hi Tech Pharmacal reported decline in revenue from the sale of generic drugs. Revenue from Health Care Products also followed the trend and declined. The company reported increase in its R&D expenses as well as in selling, general and administrative expenses.
